Recent heart-drug trials miss endpoints, raising doubts about AI-driven drug design

Two large clinical studies presented at the American Heart Association meeting this weekend failed to show any benefit for experimental heart‑attack and stroke therapies, underscoring the difficulty of translating new scientific ideas into effective medicines.

The first trial evaluated Novartis' pelacarsen, a drug that lowers blood levels of lipoprotein(a). Although the molecule succeeded in reducing the biomarker, the study found no impact on the incidence of heart attacks or strokes.

A separate study from Novo Nordisk tested an anti‑inflammatory agent that blocks the IL‑6 protein. Like the pelacarsen trial, this investigation also reported no clinical advantage despite the drug’s targeted mechanism.

The article argues that these setbacks should temper the enthusiasm surrounding artificial‑intelligence‑driven drug discovery, noting that previous hype around new technologies has repeatedly fallen short when faced with real‑world trial outcomes.